Wenthe J

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.

Wenthe J, Eriksson E, Hellström AC, ..., Lövgren T, Loskog A

J Transl Med 21 (1) 506 [2023-07-27; online 2023-07-27]

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Wenthe J, Naseri S, Labani-Motlagh A, ..., Loskog A, Lövgren T

Cancer Immunol. Immunother. 70 (10) 2851-2865 [2021-10-00; online 2021-03-05]

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Wenthe J, Naseri S, Hellström AC, ..., Eriksson E, Loskog A

Cancer Gene Ther. 27 (12) 948-959 [2020-12-00; online 2020-05-01]

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.

Eriksson E, Milenova I, Wenthe J, ..., Alemany R, Loskog A

J. Immunol. 202 (3) 787-798 [2019-02-01; online 2019-01-07]